Per- And Poly-Fluoroalkyl Substances (PFAS) Exposure and Risk of Breast, and Female Genital Cancers: A Systematic Review and Meta-Analysis
PFAS Exposure and Risk of Breast and Female Genital Cancers
Keywords:
Breast Cancer, Occupational factors , Endometrial, Female genital, malignant , endocrine gland, Perfluorooctanoic Acid, hormone, PFAS, Perfluorooctane sulfonic acidAbstract
Background: PFASs, synthetic chemicals, can be encountered by humans through occupational or environmental exposure, and some reports suggest that they can disrupt endocrine and hormonal activities. In this comprehensive review and meta-analysis, we explored the connection between exposure to PFASs and the risks of breast and female genital cancers. Methods: We systematically reviewed the literature from IARC Monographs, ATSDR documents, and PubMed (as of January 2024) for cohort, case-control, and ecological studies on PFAS exposure and breast or female genital cancers. Four reviewers independently screened studies, and data extraction included study design, patient characteristics, and effect size measures. The quality of studies was assessed using the modified version of the Newcastle-Ottawa Scale (NOS). Forest plots of relative risks (RR) were constructed for breast and female genital cancer. Meta-analyses were conducted using random-effects models, stratified analyses, dose-response assessments, and publication bias evaluation. Results: The meta-analysis included 24 studies, comprising 10 cohort, 13 case-control, and one ecological study. The summary relative risk (RR) of breast cancer for PFOA exposure was 1.08 (95% CI = 0.97-1.20; n=21), and for PFOS was 1.00 (95% CI = 0.85-1.18; n=12). The RR for ovarian cancer and PFAS was 1.07 (95% CI = 1.04-1.09; n=12). The stratification by quality score, year of publication, and exposure source did not reveal any differences. However, analysis by geographical region (p=0.01) and study design (p=0.03) did show differences, particularly in terms of incidence. Stratified analyses of the dose-response relationship did not reveal a trend in the risk of breast cancer or female genital cancers, and no publication bias was found for either cancer type. No results were available for cervical and endometrial cancers. Conclusion: In summary, our results suggest an association between PFAS exposure and ovarian cancer and a possible effect on breast cancer incidence in some specific groups. However, bias and confounding cannot be excluded and prevent conclusions regarding causality.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017 Nov 1;13(11):1387-1397.
Lee CO. Gynecologic cancers: Part. I--Risk factors. Clin J Oncol Nurs. 2000 Mar-Apr;4(2):67-71. PMID: 11107378.
Fenga C. Occupational exposure and risk of breast cancer. Biomed Rep. 2016 Mar;4(3):282-292.
Weiderpass E, Labrèche F. Malignant tumors of the female reproductive system. Saf Health Work. 2012 Sep;3(3):166-80.
Ying L, Fletcher T, Mucs D, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. Occup Environ Med 2018; 75:46-51.
Gaines LGT. Historical and current usage of per- and polyfluoroalkyl substances (PFAS): A literature re-view. Am J Ind Med. 2023; 66:353-378.
Langenbach B, Wilson M. Per- and Polyfluoroalkyl Substances (PFAS): Significance and Considerations within the Regulatory Framework of the USA. Int J Environ Res Public Health. 2021 Oct 23;18(21):11142.
Panieri E, Baralic K, Djukic-Cosic D, Buha Djordjevic A, Saso L. PFAS Molecules: A Major Concern for the Human Health and the Environment. Toxics. 2022 Jan 18;10(2):44.
International Agency for Research on Cancer. PFOA. IARC Working Group on the Evaluation of Carcinogen-ic Risks to Humans, vol. 110. Some Chemicals Used as Solvents and in Polymer Manufacture. Lyon, IARC, 2017, pp. 37-110.
Zahm S, Bonde JP, Chiu WA, Hoppin J, et al Carcinogenicity of perfluorooctanoic acid and perfluorooc-tanesulfonic acid. Lancet Oncol. 2024 Jan;25(1):16-17.
Seyyedsalehi MS, Boffetta P. Per- and Poly-fluoroalkyl Substances (PFAS) Exposure and Risk of Kidney, Liver, and Testicular Cancers: A Systematic Review and Meta-Analysis. Med Lav. 2023 Oct 24;114(5): e2023040.
Ding N, Harlow SD, Randolph JF Jr, Loch-Caruso R, Park SK. Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary. Hum Reprod Update. 2020; 26:724-752.
Chang ET, Adami HO, Boffetta P, Wedner HJ, Mandel JS. A critical review of perfluorooctanoate and per-fluorooctanesulfonate exposure and immunological health conditions in humans. Crit Rev Toxicol. 2016; 46:279-331.
Agency for Toxic Substances and Disease Registry.Toxicological Profile for Perfluoroalkyls. Atlanta, GA, ATSDR, 2021.
Dekkers OM, Vandenbroucke JP, Cevallos M, et al COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. pLoS Med. 2019;16
Moher D, Liberati A, Tetzlaff J, Altmann DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med 2009; 151:264-69.
Stang A, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandom-ized studies in meta-analyses. European Journal of Epidemiology, 2010; 25:603–605
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
Higgins J.P, Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558.
Egger M, Davey Smith G, Schneider M, Minder CE. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993 Sep;35(9):950-4.
Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. Mortality of employees of a perfluorooc-tanesulphonyl fluoride manufacturing facility. Occup Environ Med. 2003 Oct;60(10):722-9.
Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol. 2008 Jan;18(1):15-22.
Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Krüger T, Ghisari M, Mulvad G, Kern P, Nzulumiki P, Dewailly E. Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study. Environ Health. 2011 Oct 6;10:88.
Steenland K, Woskie S. Cohort mortality study of workers exposed to perfluorooctanoic acid. Am J Epi-demiol. 2012 Nov 15;176(10):909-17.
Barry V, Winquist A, Steenland K. Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environ Health Perspect. 2013 Nov-Dec;121(11-12):1313-8.
Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. Environ Health Perspect. 2013 Mar;121(3):318-23.
Raleigh KK, Alexander BH, Olsen GW, Ramachandran G, Morey SZ, Church TR, Logan PW, Scott LL, Allen EM. Mortality and cancer incidence in ammonium perfluorooctanoate production workers. Occup Environ Med. 2014 Jul;71(7):500-6.
Bonefeld-Jørgensen EC, Long M, Fredslund SO, Bossi R, Olsen J. Breast cancer risk after exposure to per-fluorinated compounds in Danish women: a case-control study nested in the Danish National Birth Cohort. Cancer Causes Control. 2014 Nov;25(11):1439-48.
Wielsøe M, Kern P, Bonefeld-Jørgensen EC. Serum levels of environmental pollutants is a risk factor for breast cancer in Inuit: a case control study. Environ Health. 2017 Jun 13;16(1):56.
Mastrantonio M, Bai E, Uccelli R, Cordiano V, Screpanti A, Crosignani P. Drinking water contamination from perfluoroalkyl substances (PFAS): an ecological mortality study in the Veneto Region, Italy. Eur J Public Health. 2018 Feb 1;28(1):180-185.
Hurley S, Goldberg D, Wang M, Park JS, Petreas M, Bernstein L, Anton-Culver H, Nelson DO, Reynolds P. Breast cancer risk and serum levels of per- and poly-fluoroalkyl substances: a case-control study nested in the California Teachers Study. Environ Health. 2018 Nov 27;17(1):83.
Mancini FR, Cano-Sancho G, Gambaretti J, Marchand P, Boutron-Ruault MC, Severi G, Arveux P, Antignac JP, Kvaskoff M. Perfluorinated alkylated substances serum concentration and breast cancer risk: Evidence from a nested case-control study in the French E3N cohort. Int J Cancer. 2020 Feb 15;146(4):917-928.
Tsai MS, Chang SH, Kuo WH, Kuo CH, Li SY, Wang MY, Chang DY, Lu YS, Huang CS, Cheng AL, Lin CH, Chen PC. A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Environ Int. 2020 Sep; 142:105850.
Itoh H, Harada KH, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Yokoyama K, Zhu J, Harada Sassa M, Tsugane S, Iwasaki M. Serum perfluoroalkyl substances and breast cancer risk in Japanese wom-en: A case-control study. Sci Total Environ. 2021 Dec 15; 800:149316.
Omoike OE, Pack RP, Mamudu HM, Liu Y, Wang L. A cross-sectional study of the association between per-fluorinated chemical exposure and cancers related to deregulation of estrogen receptors. Environ Res. 2021 May;196:110329.
Velarde MC, Chan AFO, Sajo MEJV, Zakharevich I, Melamed J, Uy GLB, Teves JMY, Corachea AJM, Valparaiso AP, Macalindong SS, Cabaluna ND, Dofitas RB, Giudice LC, Gerona RR. Elevated levels of perfluoroalkyl substances in breast cancer patients within the Greater Manila Area. Chemosphere. 2022 Jan;286(Pt 1):131545.
Li X, Song F, Liu X, Shan A, Huang Y, Yang Z, Li H, Yang Q, Yu Y, Zheng H, Cao XC, Chen D, Chen KX, Chen X, Tang NJ. Perfluoroalkyl substances (PFASs) as risk factors for breast cancer: a case-control study in Chi-nese population. Environ Health. 2022 Sep 9;21(1):83.
Feng Y, Bai Y, Lu Y, Chen M, Fu M, Guan X, Cao Q, Yuan F, Jie J, Li M, Meng H, Wang C, Hong S, Zhou Y, Zhang X, He M, Guo H. Plasma perfluoroalkyl substance exposure and incidence risk of breast cancer: A case-cohort study in the Dongfeng-Tongji cohort. Environ Pollut. 2022 Aug 1; 306:119345.
Li H, Hammarstrand S, Midberg B, Xu Y, Li Y, Olsson DS, Fletcher T, Jakobsson K, Andersson EM. Cancer in-cidence in a Swedish cohort with high exposure to perfluoroalkyl substances in drinking water. Environ Res. 2022 Mar;204(Pt C):112217.
Cathey AL, Nguyen VK, Colacino JA, Woodruff TJ, Reynolds P, Aung MT. Exploratory profiles of phenols, parabens, and per- and poly-fluoroalkyl substances among NHANES study participants in association with previous cancer diagnoses. J Expo Sci Environ Epidemiol. 2023 Sep;33(5):687-698.
Law HD, Armstrong BK, D'este C, Hosking R, Smurthwaite KS, Trevenar S, Lucas RM, Lazarevic N, Kirk MD, Korda RJ. Relative rates of cancers and deaths in Australian communities with PFAS environmental con-tamination associated with firefighting foams: A cohort study using linked data. Cancer Epidemiol. 2023 Feb; 82:102296.
Chang VC, Rhee J, Berndt SI, Moore SC, Freedman ND, Jones RR, Silverman DT, Gierach GL, Hofmann JN, Purdue MP. Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2023 Aug 15;153(4):775-782.
Winquist A, Hodge JM, Diver WR, Rodriguez JL, Troeschel AN, Daniel J, Teras LR. Case-Cohort Study of the Association between PFAS and Selected Cancers among Participants in the American Cancer Society's Cancer Prevention Study II LifeLink Cohort. Environ Health Perspect. 2023 Dec;131(12):127007.
Fenton SE, Ducatman A, Boobis A, et al. Per- and Polyfluoroalkyl Substance Toxicity and Human Health Re-view: Current State of Knowledge and Strategies for Informing Future Research. Environ Toxicol Chem. 2021; 40:606-630.
Wen LL, Lin CY, Chou HC, Chang CC, Lo HY, Juan SH. Perfluorooctanesulfonate mediates renal tubular cell apoptosis through PPARgamma inactivation. PLoS One. 2016;11: e0155190.
Stanifer JW, Stapleton HM, Souma T, Wittmer A, Zhao X, Boulware LE. Perfluorinated chemicals as emerg-ing environmental threats to kidney health: A scop ing review. Clin J Am Soc Nephrol. 2018; 13:1479-1492.
Wan HT, Zhao YG, Wei X, Hui KY, Giesy JP, Wong CK. PFOS-induced hepatic steatosis, the mechanistic ac-tions on beta-oxidation and lipid transport. Biochim Biophys Acta. 2012; 1820:1092-1101.
Hui Z, Li R, Chen L. The impact of exposure to environmental contaminant on hepatocellular lipid metabo-lism. Gene. 2017; 622:67-71
Mokra K. Endocrine Disruptor Potential of Short- and Long-Chain Perfluoroalkyl Substances (PFASs)-A Synthesis of Current Knowledge with Proposal of Molecular Mechanism. Int J Mol Sci. 2021 Feb 21;22(4):2148.
Kranthi Kumar K., Uma Devi B., Neeraja P. Integration of in silico approaches to determination of endocrine disrupting perfluorinated chemicals binding potency with steroidogenic acute regulatory protein. Bio-chem. Biophys. Res. Commun. 2017; 491:1007–1014.
Kar S., Sepulveda M.S., Roy K., Leszczynski J. Endocrine-disrupting activity of per- and polyfluoroalkyl sub-stances: Exploring combined approaches of ligand and structure-based modeling. Chemosphere. 2017; 184:514–523.
Kang J., Choi J., Park J. Transcriptional changes in steroidogenesis by perfluoroalkyl acids (PFOA and PFOS) regulate the synthesis of sex hormones in H295R cells. Chemosphere. 2016; 155:436–443.
Mokra K. Endocrine Disruptor Potential of Short- and Long-Chain Perfluoroalkyl Substances (PFASs)-A Synthesis of Current Knowledge with Proposal of Molecular Mechanism. Int J Mol Sci. 2021 Feb 21;22(4):2148.
Kaiser AM, Zare Jeddi M, Uhl M, Jornod F, Fernandez MF, Audouze K. Characterization of Potential Adverse Outcome Pathways Related to Metabolic Outcomes and Exposure to Per- and Polyfluoroalkyl Substances Using Artificial Intelligence. Toxics. 2022 Aug 4;10(8):449.
Park SK, Peng Q, Ding N, Mukherjee B, Harlow SD. Determinants of per- and polyfluoroalkyl substances (PFAS) in midlife women: Evidence of racial/ethnic and geographic differences in PFAS exposure. Environ Res. 2019 Aug; 175:186-199.
Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003 Apr;237(4):474-82.
Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny. 2023 Jun;22(2):93-104.
Kashyap N, Krishnan N, Kaur S, Ghai S. Risk Factors of Cervical Cancer: A Case-Control Study. Asia Pac J Oncol Nurs. 2019 Jul-Sep;6(3):308-314.
https://echa.europa.eu/hot-topics/perfluoroalkyl-chemicals-pfas
https://www.epa.gov/pfas/key-epa-actions-address-pfas
Mohammed AA. The clinical behavior of different molecular subtypes of breast cancer. Cancer Treat Res Commun. 2021; 29:100469.
Pierozan P, Jerneren F, Karlsson O. Perfluorooctanoic acid (PFOA) exposure promotes proliferation, migra-tion and invasion potential in human breast epithelial cells. Arch Toxicol. 2018 May;92(5):1729-1739. doi: 10.1007/s00204-018-2181-4. Epub 2018 Mar 3. PMID: 29502166; PMCID: PMC5962621.
Sutton P, Kavanaugh-Lynch MH, Plumb M, Yen IH, Sarantis H, Thomsen CL, et al.. California Breast Cancer Prevention Initiatives: Setting a research agenda for prevention. Reproduct Toxicol. (2015) 54:11–8. 10.1016/j.reprotox.2014.09.008
Gui SY, Chen YN, Wu KJ, Liu W, Wang WJ, Liang HR, Jiang ZX, Li ZL, Hu CY. Association Between Exposure to Per- and Polyfluoroalkyl Substances and Birth Outcomes: A Systematic Review and Meta-Analysis. Front Public Health. 2022 Mar 24;10:855348. doi: 10.3389/fpubh.2022.855348. PMID: 35400049; PMCID: PMC8988915.
Cohn BA, La Merrill MA, Krigbaum NY, Wang M, Park JS, Petreas M, Yeh G, Hovey RC, Zimmermann L, Cirillo PM. In utero exposure to poly- and perfluoroalkyl substances (PFASs) and subsequent breast cancer. Re-prod Toxicol. 2020 Mar;92:112-119. doi: 10.1016/j.reprotox.2019.06.012. Epub 2019 Jul 16. PMID: 31323350.
Downloads
Issue
Section
License
All Journal's articles are Open Access papers distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a CC BY-NC 4.0 Creative Commons Attribution-NonCommercial 4.0 International License.